Latest research on Herceptin

A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*

Herceptin interactions

The 594 patients who satisfied all the eligibility criteria were randomly assigned in a 1 : 1 ratio to two groups: one group received chemotherapy alone, Cisplatin (80 mg/m2) plus Fluorouracil (800 mg/m2, Qd × 5 days), or Capecitabine (1000 mg/m2, bid × 14 days); the other group received chemotherapy plus trastuzumab (Herceptin, F. [source, 2016]
Cetuximab (Erbitux), trastuzumab (Herceptin), and panitumumab (Vectibix) were purchased from Merck (Whitehouse Station, NJ), Roche (Basel, Switzerland), and Amgen (Thousand Oaks, CA), respectively. [source, 2016]
The conjugation efficiency between bispecific antibody (Bis), Herceptin (Her), Erbitux (Erb), and both Herceptin and Erbitux (Erb+Her) with MnMEIO-CyTE777-mPEG NPs was determined by collecting unconjugated antibodies in the supernatant after centrifugal filtration of the antibody reaction mixture and measuring the concentration using NanoDrop ND-1000 UV-vis spectrometer. [source, 2016]
The variable domains of heavy (VH) and light (VL) chains of anti-EGFR (Erbitux) and anti-HER2/neu (Herceptin) were linked via (Gly4Ser)3 to form scFv (Erbitux) and scFv (Herceptin), respectively. [source, 2016]
The bispecific fragment was then generated by linking scFv (Erbitux) and scFv (Herceptin) with a flexible peptide linker, ASTGS, and cloned into the 5' region of the human IgG1 Fc in pFUSE-hIgG1e4-Fc vector to form an Fc-fusion construct (Fig. 1A). [source, 2016]
Tumor cells pretreated with excess Herceptin, Erbitux, and both antibodies, respectively, for 1 hr at 37 °C, followed by incubation with MnMEIO-CyTE777-(Bis)-mPEG NPs. [source, 2016]
The Taxol Epirubicin Cyclophosphamide Herceptin neoadjuvant study reported a correlation between pCR and improved disease-free or overall survival (17). [source, 2015]
The nanoconjugate contains five key components (Figure 1B): PMLA as the backbone; 2% Morpholino antisense oligonucleotide (AONHER2) to inhibit HER2/neu protein synthesis; 0.2% Herceptin, 40% tri(L-Leucine) (LLL) for cytoplasmic delivery of AONHER2, and 5% mPEG5000 to increase serum stability. [source, 2015]
The amount of Herceptin in nanoconjugate prior to cleavage was measured by the colorimetric bicinchoninic acid (BCA) method [26] using a commercial kit from Pierce based on colorimetric reactions of peptide bonds and side chains of cysteine, cystine, Tryptophan and TYROSINE [27]. [source, 2015]
These were categorized as: (1) TAC, which included women who received sequential administration of doxorubicin (Adriamycin), Cyclophosphamide (Cytoxan), and Docetaxel (Taxotere); (2) TC, which included women who received Docetaxel (Taxotere) and cyclophsophamide (Cytoxan); or (3) TCH, which included women who received Docetaxel (Taxotere), Carboplatin (Paraplatin), and trastuzumab (Herceptin). [source, 2015]